Protalix BioTherapeutics, Inc.
PLX
$1.67
$0.000.00%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 61.84M | 61.95M | 59.76M | 53.40M | 45.67M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 61.84M | 61.95M | 59.76M | 53.40M | 45.67M |
| Cost of Revenue | 26.26M | 26.31M | 29.90M | 24.32M | 29.29M |
| Gross Profit | 35.58M | 35.64M | 29.87M | 29.08M | 16.38M |
| SG&A Expenses | 11.16M | 10.82M | 11.68M | 12.19M | 13.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.47M | 53.72M | 55.14M | 49.48M | 54.57M |
| Operating Income | 6.37M | 8.23M | 4.63M | 3.92M | -8.91M |
| Income Before Tax | 6.48M | 8.09M | 5.16M | 4.15M | -9.59M |
| Income Tax Expenses | 1.09M | 1.81M | 1.25M | 1.22M | 18.00K |
| Earnings from Continuing Operations | 5.39 | 6.28 | 3.91 | 2.93 | -9.61 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.39M | 6.28M | 3.91M | 2.93M | -9.61M |
| EBIT | 6.37M | 8.23M | 4.63M | 3.92M | -8.91M |
| EBITDA | 7.78M | 9.60M | 5.96M | 5.22M | -7.62M |
| EPS Basic | 0.08 | 0.09 | 0.06 | 0.04 | -0.13 |
| Normalized Basic EPS | 0.06 | 0.07 | 0.05 | 0.04 | -0.08 |
| EPS Diluted | 0.05 | 0.05 | 0.02 | 0.00 | -0.15 |
| Normalized Diluted EPS | 0.04 | 0.05 | 0.02 | 0.01 | -0.09 |
| Average Basic Shares Outstanding | 304.78M | 299.05M | 293.69M | 290.11M | 292.51M |
| Average Diluted Shares Outstanding | 343.02M | 343.43M | 335.46M | 331.89M | 300.18M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |